Heterogeneity of Fibroblasts in Healthy and Diseased Kidneys by Yoshikawa, Takahisa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Heterogeneity of Fibroblasts in 
Healthy and Diseased Kidneys
Takahisa Yoshikawa, Yuki Sato and Motoko Yanagita
Abstract
Chronic kidney disease (CKD) is a worldwide health problem affecting 9.1% of 
the world’s population. The treatments to prevent the progression of CKD remain 
limited, however. Resident fibroblasts in the kidneys play crucial roles in the 
pathological conditions commonly recognized in CKD, such as renal fibrosis, renal 
anemia, and peritubular capillary loss. Fibroblasts in the kidney provide structural 
backbone by producing extracellular matrix proteins and produce erythropoietin 
for normal hematopoiesis under physiological conditions. In the diseased condi-
tion, however, fibroblasts differentiate into myofibroblasts that produce excessive 
extracellular matrix proteins at the cost of the inherent erythropoietin-producing 
abilities, resulting in renal fibrosis and renal anemia. Pericytes, which are mesen-
chymal cells that enwrap peritubular capillaries and highly overlap with resident 
fibroblasts, detach from peritubular capillary walls in response to kidney injury, 
resulting in peritubular capillary loss and tissue hypoxia. Several reports have 
demonstrated the beneficial roles of fibroblasts in the regeneration of renal tubules 
Renal fibroblasts also have the potential to differentiate into a proinflammatory 
state, producing various cytokines and chemokines and prolonging inflammation 
by forming tertiary lymphoid tissues, functional lymphoid aggregates, in some 
pathological conditions. In this article, we describe the heterogenous functions of 
renal fibroblasts under healthy and diseased conditions.
Keywords: chronic kidney disease, erythropoietin, renal anemia, fibrosis, 
myofibroblast, tertiary lymphoid tissue
1. Introduction
Chronic kidney disease (CKD) is a worldwide public health problem. In 2017, 
the prevalence of CKD was estimated to be 9.1% in the world’s population, and 
has increased by 29.3% from 1990 to 2017 [1]. The prevalence of CKD in elderly 
individuals over 65 years old is especially high and is predicted to increase further as 
a result of the increasingly aged society [2]. CKD is a risk factor for end-stage renal 
disease (ESRD) and is also recognized as an independent risk factor for cardiovas-
cular diseases and their associated mortality [3]. Patients with ESRD need renal 
replacement therapies such as dialysis and renal transplantation to survive. The cost 
of these therapies is enormous and the financial burden is a critical problem for 
patients and society [4]. Nevertheless, treatment to prevent the progression of CKD 
and the occurrence of CKD-associated complications remain limited.
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Fibroblasts are distributed in various organs throughout the body and con-
tribute to both homeostasis and disease. In the kidney, resident fibroblasts play 
crucial roles in both health and disease, and their phenotypes are heterogenous 
and plastic [5]. Under physiological conditions, renal fibroblasts provide struc-
tural support for the entire kidney architecture and produce erythropoietin 
(EPO). In contrast, in diseased kidneys, fibroblasts lose these physiological func-
tions and transdifferentiate into myofibroblasts. These phenotypic changes result 
in fibrosis, renal anemia, and peritubular capillary loss, all of which are common 
pathological conditions of CKD, irrespective of the etiology [6]. Renal fibroblasts 
also act as inflammatory cells and produce proinflammatory cytokines and 
chemokines under some pathological conditions [5, 7]. In aged injured kidneys, 
fibroblasts play a crucial role in prolonging inflammation by inducing tertiary 
lymphoid tissue (TLT) formation [8]. These features highlight the importance 
of understanding the behavior of fibroblasts in the kidney in order to identify 
efficient therapeutic strategies to prevent CKD progression. In this article, we 
describe the current understanding of the heterogeneous functions of fibroblasts 
in healthy and diseased kidneys.
2. Fibroblasts in the kidney
2.1 Characteristics and functions of resident fibroblasts in kidneys
Renal resident fibroblasts are spindle-shaped cells that exist in the interstitial 
space, which is defined as the area between nephrons. Nephrons are functional 
units of the kidney and are composed of glomerular and tubular cells. Fibroblasts 
provide the structural backbone of the kidney by producing extracellular matrix 
(ECM) proteins and interact with surrounding cells to maintain the homeostatic 
state in healthy kidneys. Identification of resident fibroblasts is performed based 
on their location, shape, and positive expressions of several fibroblast markers such 
as CD73 and PDGFRβ [9]. As these markers are neither homogeneously positive 
nor specific for resident fibroblasts, confirming the negative expression of other 
cell-lineage markers such as CD45, a hematopoietic cell marker, is also necessary to 
identify renal resident fibroblasts.
In addition to the role of structural cells, fibroblasts have unique organ-specific 
functions. In the kidney, small subset of the renal resident fibroblasts residing in 
the corticomedullary area produces Epo, a hormone essential for erythropoiesis 
in response to hypoxia [10]. Although there are few Epo-producing cells and 
they exist only in the deep cortex in the physiological state, under severe hypoxic 
conditions such as severe anemia, the number of Epo-producing cells increases 
and they can be detected in the cortical area [11]. The increase in the number of 
Epo-producing cells under hypoxic conditions is likely due to the increase in the 
number of the cells that have acquired Epo-producing ability but not to cellular 
proliferation, because Epo production is activated in anemic mice under adminis-
tration of a cell cycle inhibitor or γ-ray irradiation [10]. Interestingly, while other 
growth factors for hematopoietic cells (such as granulocyte colony-stimulating 
factor) are produced in bone marrow, where hematopoietic cells are generated 
and the growth factors are required, EPO is produced from the kidney. One 
possible explanation for this is that kidneys are physiologically hypoxic compared 
with other organs, which allows them to be more sensitive to small changes in 
oxygen delivery than other organs and is advantageous to the production of EPO 
in response to hypoxia [12]. Another explanation is that kidneys function as a 
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“critmeter,” with the ability to set hematocrit within the normal range by regulat-
ing plasma volume and the red blood cell mass in a common site [13].
2.2 Origin and heterogeneity of fibroblasts in the kidney
In 1974, Le Douarin et al. reported that, in transplantation experiments of quail 
neural tubes to chicks, quail neural crest–derived cells were identified in the renal 
interstitial space [14]. Consistently, we found that fibroblasts in neonate kidneys 
express p75 neurotrophin receptor (p75NTR), a neural crest marker [15]. Moreover, 
Epo-producing cells express neuronal markers such as microtubule-associated pro-
tein 2 and neurofilament light polypeptide [10]. Based on these previous findings, 
we conducted a lineage tracing study using myelin protein zero (P0)-Cre mice, which 
label neural crest–derived cells, and found that resident fibroblasts in the cortex 
and corticomedullary area are lineage-labeled with P0-Cre [15]. We also demon-
strated that, in embryonic kidneys, P0-Cre lineage–labeled cells appeared in the 
interstitial space along the outer capsule and ureter from E13.5 and more than 99% 
of the resident fibroblasts in the cortex and outer medulla were labeled with P0-Cre 
in adult kidneys. Consistently, Epo-producing fibroblasts were also labeled with 
P0-Cre in the experiment using P0-Cre:R26R:EPO-GFP mice [15]. In contrast, renal 
fibroblasts in the medulla are not labeled with P0-Cre. Wnt4 expression is identi-
fied in the medullary stromal mesenchyme in embryotic kidneys and reactivated in 
medullary fibroblasts after renal injury [16, 17]. These findings suggest the regional 
heterogeneity of fibroblasts and their origin in the adult kidney. The functional 
heterogeneity of PDGFRβ+ Epo-producing cells was also reported. Precise histo-
logical analysis showed that different subpopulations of fibroblasts produce Epo 
responding to different stimuli [18].
2.3 Pericytes in kidneys
Pericytes are mesenchyme-derived cells that enwrap capillaries with their 
processes embedded in the vascular basement membrane. Resident fibroblasts and 
pericytes share several characteristics, including their interstitial location and cell 
surface markers such as CD73 and PDGFRβ, and, as such, these two types of cells 
are often confused. Pericytes support the capillary structure and regulate vascular 
tone with their contraction force [19]. Moreover, they interact with endothelial cells 
to maintain capillary homeostasis [6]. Humphreys et al. reported that the origins of 
pericytes in the kidneys were FoxD1-expressing cells in an experiment using FoxD1-
Cre mice [20]. On the other hand, it was reported that P0-Cre lineage–labeled 
cells in E13.5 embryonic kidneys transiently expressed FoxD1 [15]. Based on these 
findings, it is assumed that resident fibroblasts and pericytes are highly overlapped 
populations in the kidneys.
3. Renal fibrosis as a hallmark of CKD
Renal fibrosis is a common pathological condition of CKD, irrespective of the eti-
ology. It is defined as excessive accumulation of ECM such as collagen and fibronectin 
in the interstitial space and is recognized as a predictive indicator of renal prognosis 
[21]. Previous studies have shown that dysfunction of the renal fibroblasts can induce 
several pathological conditions associated with CKD, such as renal fibrosis, renal 
anemia, and peritubular capillary loss. Against this background, renal fibroblasts 
have been focused on as hopeful therapeutic targets for CKD and its complications.
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3.1 Myofibroblasts in kidneys and their origin
Myofibroblasts are recognized as the main contributor to fibrosis in multiple 
organs. They are characterized by dense endoplasmic reticulum and contractile 
microfilament bundles [22]. Their most prominent feature is the expression of 
α-smooth muscle actin (α-SMA) that forms myofilament bundles and promotes 
their high contractility [23]. Although myofibroblasts are almost undetectable in 
healthy kidneys, they expand dramatically in diseased kidneys and drive fibrosis by 
producing a large amount of ECM proteins and through their own proliferation. The 
origin of myofibroblasts has been discussed for decades, and several genetic lineage 
tracing studies recently revealed that resident fibroblasts and pericytes are the main 
sources for myofibroblasts [9]. We reported that P0-Cre lineage–labeled cells, which 
were progenitors of resident fibroblasts (as mentioned above), could differentiate 
into myofibroblasts in several kidney injury models [15]. Humphreys et al. reported 
that FoxD1-Cre lineage–labeled pericytes are the main sources for myofibroblasts 
[20]. These studies demonstrated that most myofibroblasts are derived from these 
renal fibroblasts and pericytes. Although several studies have reported other types 
of cells as progenitor cells for myofibroblasts, such as epithelial cells, endothelial 
cells, and hematopoietic cells, recent lineage tracing experiments demonstrated 
that tubular epithelial cells do not become myofibroblasts in vivo [20, 24, 25]. The 
endothelial-to-mesenchymal transition, in which endothelial cells transdifferenti-
ate into myofibroblasts, was also reported to contribute less to myofibroblast pools 
than resident fibroblasts [24]. Additionally, Kramman et al. used single-cell RNA 
sequencing (scRNA-seq) and parabiosis techniques to demonstrate the limited 
contribution of circulating monocytes to myofibroblast pools with very few matrix 
genes expression in murine fibrotic kidneys [25].
Notably, although genetic lineage tracing is not feasible in humans, a recent 
study utilizing scRNA-seq of human kidney samples supports the notion that 
these findings in mice appear to be conserved in humans. Kuppe et al. conducted 
scRNA-seq on human kidneys in patients with CKD and demonstrated that Notch3+ 
pericytes and Meg3+ fibroblasts were the main sources for highly ECM-producing 
myofibroblasts using pseudo-time trajectory analysis and diffusion map analysis 
[26]. These studies support the idea that most renal myofibroblasts derive from 
renal resident fibroblasts or pericytes.
3.2 Progenitor of myofibroblasts; Gli1+ fibroblasts in the perivascular niche
Mesenchymal stem cells (MSCs) are defined as cells with self-renewal and 
clonogenic capacity. Gli1+ fibroblasts are MSC-like cells that reside in both the 
pericyte niche and the adventitia of larger vessels across multiple organs, includ-
ing the kidney, and exhibit trilineage differentiation potential in vitro [27, 28]. 
A fate tracing study utilizing Gli1-CreERt2:tdTomato reporter mice revealed 
that, although Gli1+ fibroblasts represented only 0.2% of the PDGFRβ+ renal 
fibroblast population in healthy kidneys, after renal injury, they proliferated 
dramatically, mainly in the medulla and inner cortex, and differentiated into 
αSMA+ myofibroblasts. Additionally, using Gli1-CreERt2:iDTR (inducible diph-
theria toxin receptor) mice, the ablation of Gli1+ cells by diphtheria toxin (DT) 
administration dramatically reduced renal fibrosis by approximately 50% after 
unilateral ureteral obstruction (UUO), which is an in vivo experimental model of 
renal fibrosis. These data suggested that Gli1+ fibroblasts predominantly pro-
liferated and contributed to renal fibrosis, suggesting the heterogeneity of the 
potential to transdifferentiate into myofibroblasts among PDGFRβ+ fibroblasts 
in the kidney.
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3.3 The roles of proximal tubule injury in CKD progression
Acute kidney injury (AKI) is a highly prevalent disorder and is one of the risk 
factors for the progression of CKD [29]. The underlying molecular mechanisms for 
CKD transition after AKI have been investigated for decades. The proximal tubules 
are the most vulnerable segment in the nephron, and are assumed to trigger the AKI 
to CKD progression. To investigate whether injured proximal tubules can trigger 
renal fibrosis, we selectively damaged proximal tubules by DT administration in 
Ndrg1-CreERt2:iDTR mice, in which DTR is specifically expressed on proximal 
tubules in the kidneys [30]. Low-dose single DT administration caused mild proxi-
mal tubule injury and reversible fibrosis whereas high-dose single DT or repeated 
low-dose DT administration caused sustained renal fibrosis. This study showed that 
injury of the proximal tubules is sufficient to cause several features of CKD, and 
that the frequency and severity of proximal tubule injury are associated with the 
degree of AKI to CKD progression. As an explanation for the association between 
proximal tubule injury and CKD, tubulointerstitial interactions in injured kidneys 
have been reported to contribute to renal fibrosis [31]. Yang et al. demonstrated 
that, in a multiple profibrotic AKI model, injured proximal tubules underwent cell 
cycle arrest in G2/M and acquired the profibrotic secretory phenotype by upregu-
lating profibrotic cytokine production, such as transforming growth factor β-1 
(TGFβ-1) and connective tissue growth factor [32]. Additionally, the administra-
tion of a p53 inhibitor, a therapy employed for bypassing G2/M arrest, attenuated 
renal fibrosis in a renal ischemic reperfusion injury model. Injured proximal tubules 
have been reported to secrete several other profibrotic ligands expressed during 
renal development. The Wnt family plays a crucial role in kidney development, and 
many Wnt family genes are upregulated in fibrotic kidney models [33]. Zhou et 
al. demonstrated that the selective ablation of Wntless, a cargo receptor necessary 
for Wnt secretion, in renal tubular epithelial cells but not in interstitial fibroblasts 
attenuated renal fibrosis in a UUO model, suggesting that the Wnt family secreted 
by renal tubules contributed to renal fibrosis. Moreover, Maarouf et al. showed that 
Wnt1 expression genetically induced in proximal tubules was sufficient for renal 
fibrogenesis by inducing interstitial myofibroblast activation and proliferation [34]. 
According to these reports, one of the mechanisms of the AKI to CKD transition is 
that ligands secreted from injured renal tubules contribute to renal fibrogenesis by 
activating myofibroblasts.
4.  Two common CKD complications, renal anemia and peritubular 
capillary loss, are also caused by dysfunction of renal  
fibroblasts/pericytes
Renal anemia is a common complication that affects the majority of patients 
with CKD [35]. The cause of renal anemia is the relative deficiency of EPO. 
Several recent studies have shown that dysfunction of renal fibroblasts contribute 
to this complication. EPO production is stimulated by hypoxia and regulated by 
hypoxia-inducible factors (HIFs). In normoxic conditions, HIFs are hydroxylated 
by HIF-prolyl hydroxylase domain–containing proteins (PHDs), and hydroxylated 
HIFs are degraded by the ubiquitin-proteasome system [36, 37]. In hypoxic condi-
tions, the hydroxylation and degradation of HIFs is inhibited, resulting in the 
transcriptional activation of HIF-inducible genes, including EPO. In renal fibrosis 
models, the Epo-producing fibroblasts transdifferentiate into myofibroblasts in 
response to kidney injury and decrease the capacity to produce Epo at the same 
time [11, 15, 38]. Souma et al. demonstrated that activation of HIFs by the genetic 
Fibroblasts - Advances in Inflammation, Autoimmunity and Cancer
6
inactivation of PHDs in Epo-producing cells restored Epo production in Epo-
producing cell–derived myofibroblasts in a renal fibrosis model [39]. Additionally, 
severe anemia or the administration of selective estrogen receptor modulators, the 
neuroprotective agents, neurotrophin, and the renoprotective agent, hepatocyte 
growth factor, restored the ability to produce Epo in myofibroblasts [15]. These 
results demonstrated that the ability to produce Epo in myofibroblasts has plastic-
ity and can be restored by therapeutic interventions. As for the mechanism of the 
decrease of Epo production in myofibroblasts, Souma et al. showed that NFκB 
signaling repressed Epo production in fibroblasts in UUO models. Moreover, 
Epo-Cre:R26-IKK2ca/+ mice, in which NFκB signals in Epo-producing cells were 
selectively activated, showed that 20% of Epo-producing cells were positive for 
α-SMA, suggesting that NFκB signaling also contributed to the transition of 
EPO-producing fibroblasts into myofibroblasts [11]. Another possible mechanism 
for the repression of Epo production in myofibroblasts is that hypermethylation in 
the Epo promotor, which is induced by TGFβ-1 stimulation, inhibits Epo expres-
sion in myofibroblasts in the fibrotic kidney [38]. Fuchs et al. also showed that 
Epo production in renal fibroblasts was suppressed by TGFβ signaling in renal 
fibrosis models, utilizing PDGFRβ-Cre:TGFβ-R2fl/fl mice, and hypothesized that it 
occurred before the phenotypic shift of fibroblasts to myofibroblasts because the 
frequency of α-SMA+ myofibroblasts did not differ between the knockout mice 
and control mice [40].
Although the administration of erythropoiesis-stimulating agents (ESAs) is a 
currently well-established and effective clinical treatment, it might be associated 
with several adverse effects, such as hypertension and thrombotic complications 
[41]. To avoid safety concerns associated with ESAs, PHD inhibitors, which upregu-
late EPO production via the stabilization of HIFs, have been developed and used for 
the treatment of renal anemia [36, 42–45].
Another common pathological feature of CKD is the loss of peritubular 
capillaries [46]. Renal pericytes enwrap peritubular capillaries and support 
them structurally. In response to injury, pericytes detach from capillaries and 
their processes, which form networks surrounding the capillaries, start to direct 
from their associated capillaries to the adjacent tubules, concomitant with 
transdifferentiation into myofibroblasts [39]. This pathological change makes 
peritubular capillaries unstable and causes capillary rarefaction and loss [47]. 
Reduced peritubular capillary blood supply can cause chronic hypoxia in renal 
parenchymal cells such as tubules and stromal cells. Hypoxia aggravates renal 
fibrosis by stimulating fibroblasts and altering their gene expressions associated 
with ECM metabolism [48]. For example, hypoxia upregulated collagen type 1 
and the tissue inhibitor of metalloproteinase-1 expression and also downregu-
lated matrix metalloproteinase-1 in vitro, which led to the accumulation of ECM 
proteins. Excessive fibrosis also reduces the efficiency of oxygen diffusion due to 
the expanded distance between capillaries and tubules and induces renal damage, 
which can drive further CKD progression. Recently, a sodium-glucose cotrans-
porter 2 (SGLT2) inhibitor, which prevents glucose reabsorption by SGLT2 in 
proximal tubules, was reported to prevent tissue hypoxia and renal fibrosis in an 
ischemic reperfusion injury (IRI) model by ameliorating renal capillary rarefac-
tion and the detachment of pericytes from endothelial cells with the promotion 
of vascular endothelial growth factor-A expression in proximal tubular cells [49]. 
Additionally, SGLT2 inhibitor treatment was reported to increase hematocrit con-
comitantly with the elevation of serum EPO concentrations in patients with type 
2 diabetes mellitus [50, 51]. On the basis of these reports, SGLT2 inhibitors are 
expected to play a beneficial role in the restoration of the physiological functions 
of fibroblasts.
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5. Beneficial function of myofibroblasts in kidneys
Contrary to the long-held assumption that fibrosis is detrimental to the host, 
recent evidence suggests that fibrosis also has host-protective roles in some cases. 
To investigate the role of fibroblasts during the early phase of kidney injury, we uti-
lized P0-Cre:iDTR mice [52], which allow us to induce resident fibroblast-specific 
dysfunction at the desired time point by DT administration. Utilizing this system, 
we found that the dysfunction of resident fibroblasts in the acute phase of injury 
impaired tubular regeneration. During the transition from fibroblasts to myofi-
broblasts, fibroblasts upregulate the expression of retinaldehyde dehydrogenase 
2 (RALDH2), a rate-limiting enzyme in retinoic acid (RA) synthesis. Given that 
RAs are essential for kidney development, RAs derived from myofibroblasts might 
promote tubule regeneration. Retinoic acid receptor (RAR) γ and the downstream 
molecules such as αB-crystallin were expressed in proximal tubules in injured 
kidneys, and the administration of an RAR inverse agonist to the proximal tubule 
cell line attenuated proliferation in vitro. Another example of the beneficial role 
of fibroblasts during injury was shown by the experiment utilizing the intravital 
imaging method [53]. Schiessl et al. demonstrated that, in response to laser-induced 
tubular cell injury, PDGFRβ+ interstitial cells migrated towards tubular injury sites 
and enclosed the injured tubules. Additionally, PDGFRβ inhibitors compromised 
the recruitment of the interstitial cells and tubule regeneration. These results sug-
gest that fibroblasts have the potential to promote tubule regeneration, at least in 
the acute phase of kidney injury, via PDGFRβ signaling.
6. Renal fibroblasts associated with inflammation
Although myofibroblasts are established as the primary effector cells driving 
fibrosis, several recent studies have demonstrated that resident fibroblasts in the 
kidney also have a proinflammatory phenotype. Souma et al. reported that Epo-
producing fibroblast–derived myofibroblasts upregulated the expression of the target 
genes of NFκB such as Il6 and Ccl2 in an UUO model [11]. Leaf et al. reported that 
renal pericytes could work as innate immune cells and respond to damage-associated 
molecular patterns (DAMPs) sensitively in the acute phase of renal injury [54]. In 
response to the stimulation with DAMPs, renal pericytes activated NLRP3 inflamma-
some and secreted IL-1β and IL-18 in a TLR2/TLR4 and Myd88-dependent manner 
and aggravated renal fibrosis in the IRI model. In vitro, Myd88 knockout pericytes 
and Tlr2/Tlr4 double knockout pericytes also reduced their ability to migrate and the 
expression of the genes associated with fibrosis in response to TGF-β or DAMPs. These 
results suggested that both the inflammatory and fibrogenic properties of pericytes 
were dependent on Myd88, TLR2, and TLR4. Further studies are necessary to elucidate 
the significance of proinflammatory fibroblasts in renal injury and CKD progression.
It is of note that an anti-inflammatory role of fibroblasts and pericytes was also 
reported. Using FoxD1-Cre:CD73fl/fl mice, Perry et al. demonstrated that CD73, 
an enzyme converting AMP to adenosine on fibroblasts and pericytes, was neces-
sary to suppress inflammation and attenuate renal fibrosis after kidney injury 
[55]. Additionally, the absence of CD73 on the fibroblasts was associated with an 
increase in α-SMA expression in vitro. The authors hypothesized that the adenos-
ine locally generated by CD73 on fibroblasts and pericytes might act on adenosine 
receptors in an autocrine and paracrine manner and attenuate macrophage 
infiltration and profibrotic properties. Importantly, renal fibroblasts can act as 
modulators of inflammation and contribute to normal tissue repair by interacting 
with the surrounding cells.
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7.  Age-dependent phenotype of fibroblasts: tertiary lymphoid tissue: 
associated fibroblasts
7.1 Tertiary lymphoid tissue formation in aged injured kidneys
An epidemiological study showed that elderly patients with AKI had an 
increased risk for CKD progression [56]. The mechanism for the maladaptive 
repair after AKI in the elderly remains unknown. To identify the mechanism, we 
compared the renal response to injury between young and aged mice. As in humans, 
while young kidney repaired itself after injury, aged kidney exhibited sustained 
tubular injury and fibrosis [8]. Unexpectedly, we found multiple TLTs in aged 
kidneys but not young kidneys in the chronic phase after kidney injury. TLT is an 
ectopic lymphoid tissue that develops at the site of chronic inflammation. TLTs are 
mainly composed of lymphocytes that are structurally and functionally supported 
by unique phenotypic fibroblasts inside TLTs (Figure 1). Unlike simple infiltration 
of the inflammatory cells, TLTs can promote lymphocyte proliferation and differen-
tiation, resulting in the generation of antibody-secreting plasma cells, as recognized 
in secondary lymphoid organs [57]. Importantly, although TLTs are identified in 
various disease conditions, such as autoimmune diseases, infections, and cancers, 
TLTs can play beneficial or pathological roles in a context-dependent manner [58]. 
For example, in chronic inflammatory or autoimmune diseases, TLTs contribute 
to disease persistence and have detrimental effects on the host [59]. In contrast, 
during infections, TLTs are assumed to play beneficial roles to eliminate pathogens 
by promoting immune responses [60]. The role of TLTs in aged injured kidneys 
remains unclear, and will be discussed in the next section.
7.2 Characteristics and origin of fibroblasts inside tertiary lymphoid tissues
Fibroblasts inside TLTs exhibit unique characteristics that are distinct from 
those outside TLTs, such as the strong expression of p75NTR (Figure 1) [8]. After 
kidney injury, resident fibroblasts acquire the ability to produce RAs by upregulat-
ing RALDH2, which is assumed to promote the transition of the adjacent fibroblasts 
into p75NTR+ TLT-associated fibroblasts. Some of the p75NTR+ TLT-associated 
fibroblasts acquire abilities to secrete homeostatic chemokines such as CCL19 and 
CXCL13, which are the driving force for recruiting lymphocytes and promoting TLT 
Figure 1. 
Tertiary lymphoid tissues in aged murine kidney 45 days after ischemic reperfusion injury. (A) Immuno 
fluorescence staining of B220 (green) and CD3ε (red). Tertiary lymphoid tissues (TLTs) are mainly composed 
of B220+ B cells and CD3ε+ T cells. (B) Immunofluorescence staining of p75NTR (green) and CD21 (red). 
Fibroblasts inside TLTs express p75 neurotrophin receptor (p75NTR). In mature TLTs, some of the fibroblasts 
differentiate into p75NTR−/CD21+ follicular dendritic cells. Scale bar: 50 μm.
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formation. Inside of more mature TLTs, CD21+/p75NTR− follicular dendritic cells 
(FDCs) appear as part of stromal cells (Figure 1). FDCs are stromal cells residing 
in the B cell follicles of secondary lymphoid organs; they drive germinal center 
reactions [61]. These TLT-associated fibroblasts in the kidneys are P0-Cre lineage–
labeled cells, suggesting that renal resident fibroblasts can differentiate into these 
various types of fibroblasts [8].
7.3 Clinical significance of tertiary lymphoid tissues in CKD and the elderly
Several studies have reported that TLTs are induced in various kidney diseases 
[62–65]. Additionally, we reported that TLTs developed not only in murine kidneys 
but also in human kidneys in an age-dependent manner [8]. In the analysis on 
kidneys from nephrectomy cases for renal cell carcinoma and autopsy, excluding 
pyelonephritis, glomerulonephritis, autoimmune kidney diseases, and hematologi-
cal malignancies, TLTs were identified only in the elderly over 60 years old. The 
components of human TLTs are quite similar to those of murine TLTs. To evaluate 
TLTs objectively, we classified renal TLTs into three stages based on the immunos-
taining patterns as follows [66]. TLTs not containing CD21+ FDCs or a germinal 
center response, dense Ki67+ proliferative B cell clusters, were defined as stage 1. 
TLTs containing CD21+ FDCs but no germinal center response were defined as stage 
2. TLTs containing both CD21+ FDCs and a germinal center response were defined 
as stage 3. In this classification, the severity of the TLT stages and the area of TLTs 
were related with the severity of ischemic injury in murine renal IRI models. In 
humans, more and higher-stage TLTs were identified in the kidneys of patients with 
CKD than without CKD among elderly patients 60 years or older in the analysis 
using kidneys from nephrectomy cases due to renal cell carcinoma [66]. These data 
demonstrated that the developmental stage of TLTs was associated with the severity 
of kidney injury, thereby indicating that TLTs have potential as a marker of severity 
of renal injury.
7.4 Potential of tertiary lymphoid tissues as therapeutic targets for CKD
Although TLTs are assumed to be associated with the severity of renal injury, 
it has been challenging to determine whether renal TLTs are pathogenic and if 
they directly affect renal function. We reported that, in unilateral renal IRI mod-
els of aged mice, the administration of GK1.5, anti-CD4 monoclonal antibody, 
diminished TLT formation and inflammatory marker expressions and improved 
renal fibrosis [8]. This result suggests that renal TLTs could be pathogenic and the 
therapies targeting renal TLTs thus have the potential to improve renal function in 
patients with CKD. As this intervention is not specific to TLTs and affects systemic 
immune systems, however, a more specific therapy for TLTs is necessary to deter-
mine whether TLTs in aged injured kidneys are detrimental or not.
8. Conclusion
Resident fibroblasts in the kidney are essential components to maintain homeo-
stasis under physiological conditions. In CKD, dysfunction of renal fibroblasts 
causes the main pathological conditions of renal fibrosis, renal anemia, and 
peritubular capillary loss. Importantly, renal fibroblasts are heterogeneous and 
have the potential to change their phenotypes depending on the local microen-
vironment (Figure 2) [5]. Although myofibroblasts mainly contribute to renal 
fibrosis and deteriorate renal function by producing excessive ECM, they can also 
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have host-protective roles in the early phase of kidney injury. Renal fibroblasts can 
differentiate into proinflammatory fibroblasts that secrete inflammatory cyto-
kines and chemokines, which can promote TLT formation under several diseased 
conditions. Fibroblasts or pericytes also have an anti-inflammatory function via 
CD73 expression. A better understanding of the heterogeneity and roles of renal 
fibroblasts might lead to the development of a new therapeutic approach for kidney 
diseases. Recent novel technologies such as scRNA-seq have revealed the heteroge-
neity of renal fibroblasts that had not previously been identified by conventional 
technologies [26]. The application of these technologies to various clinical renal 
diseases is expected to further clarify the heterogeneity of renal fibroblasts, which 
will result in an enhanced understanding of the pathophysiology of kidney diseases 
and the development of novel treatments.
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Appendices and nomenclature
CKD chronic kidney disease
ESRD end-stage renal disease
EPO erythropoietin
TLT tertiary lymphoid tissue
ECM extracellular matrix
p75NTR p75 neurotrophin receptor
P0 myelin protein zero
α-SMA α-smooth muscle actin
Figure 2. 
Heterogeneity of fibroblasts in kidneys. Renal fibroblasts derive from P0- or FoxD1-Cre lineage–labeled cells. 
Renal fibroblasts change their phenotypes depending on the local microenvironment. Myofibroblasts have 
the potential to produce excessive extracellular matrix proteins at the cost of EPO production. In response to 
released DAMPs after injury, fibroblasts can differentiate into proinflammatory fibroblasts that produce IL-18 
and IL-1β. In contrast, in aged kidneys, retinoic acids produced by activated fibroblasts after injury induce the 
differentiation of adjacent fibroblasts into p75NTR+ fibroblasts, which produce homeostatic chemokines such 
as CXCL13 and CCL19, resulting in tertiary lymphoid tissue (TLT) formation. These chemokine-producing 
fibroblasts can further differentiate into CD21+/p75NTR− FDCs in mature TLTs.
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scRNA-seq single cell RNA-sequencing
MSC mesenchymal stem cell
iDTR inducible diphtheria toxin receptor
DT diphtheria toxin
UUO unilateral ureteral obstruction
AKI acute kidney injury
TGFβ-1 transforming growth factor β-1
HIF hypoxia-inducible factor
PHD prolyl hydroxylase domain–containing protein
ESA erythropoiesis-stimulating agent
SGLT2 sodium-glucose cotransporter 2
RALDH2 retinaldehyde dehydrogenase 2
RA retinoic acid
RAR retinoic acids receptor
DAMP damage-associated molecular pattern
FDC follicular dendritic cell
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